4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid

We are 4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid CAS:105580-45-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  4-(2,3-Dichlorophenyl)-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid
CAS.NO:  105580-45-8
Synonyms:
4-(2,3-DICHLORO-PHENYL)-2,6-DIMETHYL-1,4-DIHYDRO-PYRIDINE-3,5-DICARBOXYLIC ACID MONOMETHYL ESTER

Molecular Formula: C16H15Cl2NO4
Molecular Weight: 356.20100

Physical and Chemical Properties:
Density: 1.4±0.1 g/cm3
Boiling point:483.0±45.0 °C at 760 mmHg
Melting point: /
Flash point: 245.9±28.7 °C
Refractive index: 1.581

Specification:
Appearance: White crystal powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage: Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Clevidipine CAS:166432-28-6
Intermediates of Clevidipine butyrate CAS:167221-71-8

Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.53617-35-9 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.1,4-Phenylene Diisothiocyanate CAS:4044-65-9 After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.4-aminobenzamide CAS:2835-68-9 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.